A commonly used regimen is a loading phase of 25 mg per week (subcutaneous injection) for 46 weeks, followed by a maintenance dose of around 2 mg every 12 weeks
Thus, to illustrate these combining points (i.e., [13, 44, 63]), considering that white matter injury is the major cause of functional loss after SCI [45, 52], it is important to note that cysts and the loss of axons instead of hemorrhagic areas were observed in the white matter in all of the controls beginning on day 7 and that the rats exhibited a tail motor score that persisted with only small improvements, sustained debilitation, sustained tail spasticity until the end of the experiment (day 360), a decrease in the number of large myelinated axons in the caudal nerve, a higher MUP (giant potential) in the tail muscle, and a group of atrophic fibers that likely represented a large unit that acquired many fibers through collateral reinnervation and then degenerated
NICE and NHS guidance on hair loss does not include GHK-Cu as a recommended or evidence-based treatment option
it's about a chemical breakdown with tangible consequences
For patients throughout the St